Ventricular Tachycardia

Cardiovascular·MeSH: Tachycardia, Ventricular

Prevalence

0.5 / 100K

10 drugs in development·6 companies·4 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
isoproterenol	Amphastar Pharmaceuticals, Inc. (AMPH)
procainamide	NEXUS BIOPHARMA INC (NEXS)
propafenone	Mylan II B.V. (MYL)

Phase 3(4)

Drug	Company
cardamyst	Milestone Pharmaceuticals Inc. (MIST)
SGT-501	Solid Biosciences Inc. (SLDB)
vclas cryoablation system	Adagio Medical Holdings Inc (ADGM)
vt cryoablation system	Adagio Medical Holdings Inc (ADGM)

Phase 2(1)

Drug	Company
etripamil ns	Milestone Pharmaceuticals Inc. (MIST)

Preclinical(2)

Drug	Company
pfca	Adagio Medical Holdings Inc (ADGM)
pulsed field cryoablation	Adagio Medical Holdings Inc (ADGM)

BioSniper tracks 10 drugs in development for Ventricular Tachycardia across 6 companies.

There are 4 clinical trials targeting Ventricular Tachycardia tracked by BioSniper.

The estimated prevalence of Ventricular Tachycardia is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.